The FDA-approved, targeted radiopharmaceutical agent can contribute to a patient’s cumulative radiation exposure.
Stephanie Trexler, PharmD, BCOP
Advertisement
Articles by Stephanie Trexler, PharmD, BCOP
Advertisement
Latest Updated Articles
Use of Lutetium Lu-177 Vipivotide Tetraxetan to Treat Metastatic Castration-Resistant Prostate CancerPublished: October 17th 2022 | Updated:
Advertisement
Advertisement
Trending on Pharmacy Times
1
FDA Announces Recall 580,000 Bottles of Prazosin Over Potential Carcinogenic Impurity
2
Regular Melatonin Supplementation May Hide Hidden Heart Complications
3
Early Detection of Type 1 Diabetes: The Power of Screening and Preparation
4
COVID-19 During Pregnancy Raises Neurodevelopmental Risks in Children
5
